Triple-negative breast cancer does not have estrogen receptors, progesterone receptors, or enough HER2 for treatments directed at those targets. Treatment instead depends on disease stage, tumor biology, biomarkers, prior therapy, and the individual patient.
“Triple-negative” describes receptor testing. It does not mean that every TNBC tumor behaves in the same way.
New treatments, trials, and research on triple-negative breast cancer — gathered automatically, summarized in a sentence or two, and linked straight to the original source.
Iovance is expanding its TIL cell therapy pipeline with IOV-5001 trial across multiple solid tumors including triple-negative breast cancer alongside colorectal and head/neck cancers.
Phase III A-BRAVE trial randomized 466 high-risk early TNBC patients to evaluate tumor-infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy.
circZNF148 circular RNA drives glucose metabolism reprogramming in triple-negative breast cancer to enhance metastasis.
Study investigates why only approximately half of TNBC patients respond to chemotherapy, examining treatment resistance mechanisms.
Showing the 4 latest of 12 stories. Summaries are AI-generated.
A tumor is not just cancer cells. Turn on a layer — or switch on the focus lens and move it across the tissue — to see how cells, immune activity, blood supply, DNA repair, and surface targets connect to treatment.
The cancer cells themselves — dividing and forming the tumor mass.
Each dot is a hypothetical tumor profile — not a real patient. Choose a biological dimension and watch the constellation reorganize. The same tumors line up differently depending on what you measure.
Conceptual visualization — dot positions are illustrative, not measured prevalence values. Dot size hints at proliferation.
TNBC treatment is organized by disease setting (across the top) and strategy (down the side). A therapy appears only where it is relevant. Select any card to see how it works, where it is used, and the evidence behind it.
This map shows where categories of treatment are relevant — not individualized treatment sequences, dosing, or recommendations. Positions are educational. Decisions are made with an oncology team.
Biological testing can connect a tumor to treatment options or research. Select a biomarker to trace the path from sample to result — and to see only the evidence-supported connections it carries.
Distance from the center reflects clinical maturity — not how good a therapy is. The inner ring holds approaches already integrated into care; outer rings hold strategies still being tested. Select a strategy to see the idea and its uncertainty.
Simplified model. This describes a research direction, not an available or recommended treatment.
These are real studies drawn from ClinicalTrials.gov, chosen to illustrate the range of TNBC research — not a matching service or a ranking. Filter by strategy, and open any study's official record to learn more.
How the 8 spotlighted studies distribute across category. Counts reflect this curated set only, verified July 2026 — source: ClinicalTrials.gov.
| category | Trials |
|---|---|
| Antibody-drug conjugate | 2 |
| Early-stage & neoadjuvant immunotherapy | 1 |
| Post-surgical / residual-disease | 1 |
| Vaccine | 1 |
| Cellular therapy | 1 |
| BRCA & DNA-repair-focused | 1 |
| Metastatic TNBC | 1 |